JM Biotech announced on the 11th its successful acquisition of all international business rights associated with Daejong Medical’s DJ brand products. This strategic move empowers JM Biotech to aggressively expand the reach of its cosmetic brand, RIBESKIN, in both international and domestic markets.
JM Biotech’s RIBESKIN is a brand that pursues maximum efficacy and minimum the pain of the patients by developing innovative products that breaks all stereotypes of conventional medical aesthetic procedures based on the field experience and professional R&D of the cosmetic surgery experts.
Renowned a pioneering needle-free topical carboxy treatment from Korea, RIBESKIN CO2 Aging (marketed abroad as RIBESKIN CO2 Carboxy) has been at the forefront of the cosmetic and aesthetic industry since 2012, and making strides in over 25 countries spanning Europe, the Middle East, and the Americas. RIBESKIN, a medical aesthetic brand, is gaining high recognition in the Korean market, specializing only in the distribution of products to the plastic surgery, medical aesthetic and dermatology clinics.
An executive of the company explained, “Daejong Medical’s DJ Carbon products have a carboxy concept similar to RIBESKIN’s original CO2 carboxy, and have been positioned in the Vietnamese consumer market for years without an official exclusive distributor. This has caused some confusion to the Asian distributors and the customers of RIBESKIN, and thus gave us the reason for the acquisition of the DJ Carbon brand.”
The head of the overseas marketing department added, “Through this contract, we will quickly cease the Daejong Medical’s supply of the DJ Carbon products and integrate its customers with the customers of the RIBESKIN. At the same time, to our pleasure, we will further develop and strengthen the product portfolio of RIBESKIN CO2 Aging, continuing our pride and originality as the original developer of the products.”